Batch Variability and Bioequivalence: What Acceptable Limits Really Mean for Generic Drugs
January 24, 2026 by Maxwell Harrington
Bioequivalence standards rely on a flawed 80-125% rule that ignores batch-to-batch differences in brand-name drugs. New research shows this puts patient safety at risk - and regulators are finally starting to change.